—— STRATEGY • INTELLIGENCE
Vaxa On.
The market never stops moving. Neither should your strategy.
THE WORLD VAXA ON IS WATCHING
Not trends — but structural shifts
The forces that reshape industries do not announce themselves. They accumulate — quietly, consistently, beneath the noise of quarterly results and political cycles.
By the time they are obvious, the strategic window has already moved. Most organizations encounter them in a biennial strategy review. The ones that stay ahead are monitoring them continuously.
Every organization building a growth strategy today is building it inside these forces — whether they are watching them or not. The question is not whether they will affect your business. It is whether you will see them early enough to act.
Vaxa On is always on because these forces never are not.
.png)
Six ways to keep Vaxa On
Each offering functions standalone — or combine them for comprehensive strategic coverage.
MONTHLY DELIVERABLES
A structured signal report covering competitive moves, market shifts, emerging technology developments, and regulatory changes relevant to your specific business — with Vaxa's analysis of what each means and what to do about it.
QUARTERLY DELIVERABLES
A deep dive on a topic of strategic importance — a competitor, a market segment, a technology, an emerging threat. Primary and secondary research combined into a structured analytical brief with clear strategic implications.
WHO THIS ENGAGES THIS OFFERING
Corporate strategy groups, market intelligence units at large enterprises, and mid-size leadership teams that need ongoing external intelligence without building an internal research function.
VAXA - 01
Intelligence
Continuous competitive and market intelligence. Monthly signal reports. Quarterly deep dives. On-demand research on specific topics. The internal market intelligence function most organizations cannot afford to build — delivered externally, on schedule, every month.
Monthly signal reports • Quarterly deep dives • On-demand
—— IN PRACTICE
The engagement that defined a market began years before the client brief.
The engagement that defined Vaxa's life sciences practice did not begin with a client brief. It began years earlier — with a pattern visible in US congressional appropriations and federal agency budget allocations that most people in the technology industry were not reading.
The Department of Energy received the first major appropriation for human genome sequencing in 1988. The National Institutes of Health followed, was designated primary vehicle, and established the National Human Genome Research Institute to direct a program that would ultimately draw in the Wellcome Trust in the UK, the Medical Research Council in Japan, and sequencing centers in China, France, and India.
When governments structure funding at that scale — across agencies, across borders, with dedicated budget lines for the ethical and legal implications of a technology — they are not experimenting. They are committing.
A commitment of that kind has downstream commercial consequences that are both large and early to read, if you know where to look. FDA resource allocation was shifting in parallel. The signal was quiet, consistent, and accumulating.
By the time the moment came to sit across from technology companies and make the case for life sciences as a growth market, Vaxa had years of evidence behind the argument. We spoke to several of the largest technology companies in the world. One said yes. That engagement became one of the most significant market entries in enterprise technology history — and it was only possible because we had never stopped paying attention.
That is what always on means in practice. Not monitoring dashboards. Not quarterly reports. The kind of continuous, accumulating intelligence that turns a congressional line item into a conviction — and a conviction into a market.
The signal was in the structure of the funding — not the headlines. Congressional appropriations, interagency budget allocations, international consortium formation. Each a legible step, if you were focusing attention in the right places at the right time.
1998
US Department of Energy receives first major congressional appropriation for human genome sequencing.
1989
NIH designated primary vehicle. National Human Genome Research Institute established to direct the program.
1990s
International consortium forms. Wellcome Trust (UK), MRC (Japan), centers in China, France, and India join the program. Multi-government commitment confirmed.
Signal
FDA resource allocation shifting in parallel. Vaxa tracking continuously. Conviction forming.
—— IS VAXA ON FOR YOU?
Six questions. If any of them land, it is worth a conversation.
01
How do we stay current between full engagements?
VAXA ON ANSWERS THIS
Intelligence and Foresight keep the thinking alive between projects. Monthly signal reports. Quarterly deep dives. The strategy stays current because the monitoring never stops.
— INTELLIGENCE • FORESIGHT
02
We're leaving revenue on the table. What to do?
VAXA ON ANSWERS THIS
Channels provides continuous partner performance monitoring and quarterly scoring. Within one quarter you will know exactly where the gap is — and have a specific plan to close it.
— CHANNELS
03
A lot of innovation ideas. Not enough conviction on which ones to pursue.
VAXA ON ANSWERS THIS
Innovation applies a structured analytical framework to your pipeline every month. Ideas get scored against market reality — not internal enthusiasm. The pipeline gets sharper every quarter.
— INNOVATION
04
We want to work with Vaxa but a full engagement isn't right yet.
VAXA ON ANSWERS THIS
Vaxa On is designed precisely for this. An accessible starting point that puts Vaxa's thinking inside your organization — without the scale of a full strategic engagement. Most full relationships begin here.
— ALL OFFERINGS
05
We need serious strategic thinking but can't justify a CSO yet.
VAXA ON ANSWERS THIS
Vaxa On: Growth is built for exactly this. Quarterly growth reviews and monthly strategic check-ins — the ongoing strategic function your organization needs, without building an internal capability from scratch.
— GROWTH
06
We're watching this space. How do we know when to move?
VAXA ON ANSWERS THIS
Foresight tracks the structural shifts in the spaces you're watching — continuously. When the window opens, you'll know before your competitors do. That's the point of always on.
— FORESIGHT
—— NOT READY FOR VAXA ALWAYS ON?
Start with a single question.
Get a credible answer in four weeks.
A Vaxa Scan is a fast, external landscape scan on a specific topic — a trend, a technology, an emerging space. Scoped in week one. Delivered in four weeks. No ongoing engagement, no internal access required. A clear starting point before you commit to more.
4 Weeks
From topic to delivered scan
You bring the topic. Vaxa defines the scope in week one and delivers against it — covering magnitude, maturity, corporate participants, venture activity, trajectory, and white space.
Stay ahead of what's forming. Subscribe to Vaxa Insights — our look at the critical issues and emerging opportunities facing businesses today.